Brelovitug not checked
Mirum Pharmaceuticals, Inc. · BJT-778
FollowEvery change as it happens, and a Monday email
Trials
4 active
4 in total · 4 in the EU
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
- How it’s given
- “Brelovitug (BJT-778), 300 mg administered subcutaneously once weekly for 96 weeks.”In the company’s words, NCT07454837 on ClinicalTrials.gov
- Tested for
- Chronic Hepatitis D Infection (3 trials), Chronic Hepatitis D
- Main trialPhase 3
- “This is a Phase 3, global, randomized, open-label, multicenter trial designed to evaluate the safety and efficacy of chronic treatment with brelovitug (BJT-778) for chronic hepatitis delta virus (HDV) infection. The objective of this study is to test the safety and effectiveness of brelovitug compared to delayed treatment.”In the company’s words, NCT07298330 on ClinicalTrials.gov
- Other names
- BJT-778 · BTG
Other drugs for Chronic Hepatitis D Infection
- ElebsiranVir Biotechnology, Inc. · Phase 3
- TobevibartVir Biotechnology, Inc. · Phase 3
- HepalatideShanghai HEP Pharmaceutical Co., Ltd. · Phase 3
- LibevitugHuahui Health · Phase 3
- GS-4321Gilead (Kite) · Phase 1/2
- RBD1016Ribocure Pharmaceuticals AB · Phase 2
Coming up3
- 30 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Aug 2027Phase 2/3 trial completes · ClinicalTrials.gov
- May 2029Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Aug 2026 | A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) | |
| Phase 3Recruiting | 30 Jun 2027 | A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) | |
| Phase 2/3Recruiting | 31 Aug 2027 | Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide | |
| Phase 2/3Active, not recruiting | May 2029 | A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026